Analyst Price Target is $26.71
▲ +533.04% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $26.71, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 533.04% upside from the last price of $4.22.
Current Consensus is
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Vor Biopharma.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More